XNASSLRN
Market cap199mUSD
Jan 16, Last price
1.99USD
1D
-1.49%
1Q
-67.90%
IPO
-91.73%
Name
ACELYRIN Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-382m
L+52.38%
CFO
-170m
L+175.85%
Earnings
Mar 28, 2025
Profile
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY |
|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | |
| Income | |||
Revenues | |||
Cost of revenue | 422,179 | 254,681 | |
Unusual Expense (Income) | |||
NOPBT | (422,179) | (254,681) | |
NOPBT Margin | |||
Operating Taxes | (4,170) | ||
Tax Rate | |||
NOPAT | (422,179) | (250,511) | |
Net income | (381,641) 52.38% | (250,461) 498.63% | |
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | 574,134 | 263,484 | |
BB yield | -109.55% | ||
| Debt | |||
Debt current | |||
Long-term debt | 2,388 | ||
Deferred revenue | |||
Other long-term liabilities | 411,520 | ||
Net debt | (718,938) | (326,066) | |
| Cash flow | |||
Cash from operating activities | (169,705) | (61,520) | |
CAPEX | (2,294) | ||
Cash from investing activities | (447,744) | (47,874) | |
Cash from financing activities | 568,436 | 274,262 | |
FCF | (425,553) | (250,511) | |
| Balance | |||
Cash | 721,326 | 326,066 | |
Long term investments | |||
Excess cash | 721,326 | 326,066 | |
Stockholders' equity | (488,556) | 146,396 | |
Invested Capital | 1,146,087 | 153,733 | |
ROIC | |||
ROCE | |||
| EV | |||
Common stock shares outstanding | 70,250 | 20,443 | |
Price | 7.46 | ||
Market cap | 524,062 | ||
EV | (194,876) | ||
EBITDA | (422,064) | (254,681) | |
EV/EBITDA | 0.46 | ||
Interest | |||
Interest/NOPBT | |||